Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

mRNA Expression in Lymphocytes of Glaucoma Patients

This study has been completed.
University of Bonn
Information provided by:
University Hospital, Basel, Switzerland Identifier:
First received: May 17, 2006
Last updated: August 19, 2009
Last verified: August 2009
The aim of the study is to compare messenger ribonucleic acid (mRNA) expression of various genes in lymphocytes between glaucoma patients and sex and age-matched healthy subjects. A secondary objective is to analyze the impact of different forms of glaucoma or of a vasospastic propensity on the findings.

Healthy Subjects

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Messenger Ribonucleic Acid Expression in Lymphocytes of Glaucoma Patients

Resource links provided by NLM:

Further study details as provided by University Hospital, Basel, Switzerland:

Biospecimen Retention:   Samples With DNA
white cells

Enrollment: 60
Study Start Date: January 2004
Study Completion Date: December 2007
Primary Completion Date: December 2007 (Final data collection date for primary outcome measure)
high tension glaucoma highest IOP > 21 mmHg
normal tension glaucoma highest measured IOP < 21 mmHg
pseudoexfoliation glaucoma PEX material visible
juvenile glaucoma
healthy subjects (age group 1)
healthy subjects (age group 2)

Detailed Description:

Glaucoma is a leading cause of blindness world-wide. Chronic primary open-angle glaucoma is the most common form among Caucasian patients. The glaucoma patients will be divided into four groups: (1) high tension glaucoma, (2) normal tension glaucoma, (3) pseudoexfoliation glaucoma, and (4) juvenile glaucoma. Healthy subjects are separated into two age groups. Vasospastic propensity will be assessed with a questionnaire: patients and subjects answering yes to the questions: "do you have always cold hands, even during summer time?" and "do other people tell you that you have cold hands?" will be classified as vasospastic, and as normals if they deny a history of cold hands. Blood will be drawn from an arm vein, lymphocytes will be isolated and mRNA of following genes will be assessed in these lymphocytes:

Nuclear proteins: NF-kappa B, XPGC, P53, XIAP; Multi-drug resistance proteins: ABC 1, ABC 8, MDR 3; Adhesion protein: ICAM 1; Blood brain barrier breakdown protein: P2Y; Energy metabolism proteins: Adrenodoxin, Adrenodoxin-reductase, Cytochrome p450, Cytochrome-reductase, Alcohol-dehydrogenase; Tissue remodeling proteins: MMP 9, MMP 8, MMP 14, TIMP 1, TIMP 2, TIMP 3, TIMP 4.


Ages Eligible for Study:   18 Years to 85 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Probability Sample
Study Population
glaucoma patients, healthy subjects

Inclusion Criteria:

Glaucoma patients

  • diagnosis of chronic glaucoma with typical glaucomatous disc and visual field damage
  • a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment HTG)
  • a present or past diurnal tension curve with an average intraocular pressure below 21 mmHg without treatment (NTG)
  • a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment and signs of pseudoexfoliation in the anterior segment (PEX)
  • a juvenile-onset open-angle glaucoma with a present or past diurnal tension curve with an average intraocular pressure above 21 mmHg without treatment (Juvenile Glaucoma)

Healthy subjects

  • no history of ocular disease
  • no history of systemic disease
  • no history of alcohol/drug abuse
  • normal blood pressure (100-140 / 60-90 mmHg)
  • best corrected visual acuity above 20/25 in both eyes
  • no pathological findings upon a slit-lamp examination and indirect fundoscopy
  • IOP < 20 mmHg in both eyes

Exclusion Criteria:

  • Ametropia > 3 dpt
  • Iridocorneal angle extremely narrow with complete or partial closure as determined by gonioscopy
  • Pigmentary dispersion
  • any abnormality which in the physician's view would prevent reliable applanation tonometry
  • History of chronic or recurrent severe inflammatory eye disease such as scleritis or uveitis
  • History of ocular trauma or intraocular surgery within the past 6 months
  • History of infection or inflammation within the past 3 months
  • History of clinically significant or progressive retinal disease such as retinal degeneration, diabetic retinopathy or retinal detachment
  • Need for any concomitant medications that may interfere with the evaluation of ocular blood flow
  • significant history and/or active alcohol or drug abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00327509

University Hospital Basel, Eye Clinic
Basel, BS, Switzerland, 4031
Sponsors and Collaborators
University Hospital, Basel, Switzerland
University of Bonn
Study Director: Selim Orgül, MD University Hospital, Basel, Switzerland
  More Information

Responsible Party: Selim Orgul, University Hospital, Basel, Switzerland Identifier: NCT00327509     History of Changes
Other Study ID Numbers: 004-KAR-2004-001
Study First Received: May 17, 2006
Last Updated: August 19, 2009

Keywords provided by University Hospital, Basel, Switzerland:

Additional relevant MeSH terms:
Ocular Hypertension
Eye Diseases processed this record on May 23, 2017